Erasca (ERAS) Corporate presentation summary

Vision and leadership

• Aims to erase cancer in at least 100,000 patients annually as a leading global oncology company.

• Founded by experts in RAS biology, supported by a world-class scientific advisory board with pioneers in RAS/MAPK pathway research.

• Leadership team has a strong track record in drug development and global approvals.

Pipeline and scientific differentiation

• Pipeline focuses on shutting down the RAS/MAPK pathway, targeting RAS-mutated and KRAS-mutated solid tumors.

• ERAS-0015 is a pan-RAS molecular glue with best-in-class potential, showing 5–10x greater antitumor activity than competitors.

• ERAS-4001 is a pan-KRAS inhibitor with first- and best-in-class potential, designed to spare wild-type HRAS/NRAS and provide a wider therapeutic window.

• Both candidates exhibit strong preclinical activity, favorable PK/ADME properties, and robust intellectual property protection through 2043.

Preclinical and clinical data highlights

• ERAS-0015 demonstrates superior potency and tumor regression at lower doses compared to RMC-6236 in multiple KRAS mutant models.

• Preferential tumor distribution and longer residence time observed for ERAS-0015 in vivo.

• ERAS-4001 shows high affinity and selectivity for KRAS mutants, potent activity in both GTP- and GDP-bound states, and tumor regression in various models.

• Both agents are well tolerated in animal studies at effective doses.